IONS vs LRMR
IONS: Pioneer in RNA-targeted antisense medicines with seven commercialized products and expanding late-stage pipeline across rare neurological and cardiometabolic diseases, now executing independent U.S. launches while generating royalty revenue from major pharma partnerships. LRMR: Larimar Therapeutics is developing a novel cell-penetrating peptide platform to treat rare, genetically driven diseases, with a lead program targeting the underlying protein deficiency in Friedreich's ataxia.
Side-by-side fundamentals
| Metric | IONS | LRMR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $54.01 | $4.02 | |
| Market cap as of 2026-07-23 | $8.8B | $418M | |
| PEG as of 2026-07-23 | n/a | -0.05 | |
| Net margin as of 2026-07-23 | -30.9% | n/a | |
| Gross margin as of 2026-07-23 | +98.3% | n/a | |
| Operating margin as of 2026-07-23 | -33.3% | n/a | |
| ROE as of 2026-07-23 | -58.7% | -134.1% | IONS higher |
| ROA as of 2026-07-23 | -10.1% | -96.0% | IONS higher |
| Debt / equity as of 2026-07-23 | 4.76 | 0.00 | LRMR lower |
| Revenue growth (YoY) as of 2026-07-23 | +47.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +17.1% | n/a | |
| Beta as of 2026-07-23 | 0.38 | 0.76 | |
| 1-year return as of 2026-07-22 close | +28.5% | +18.9% | IONS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.